Johnson And Johnson (JNJ) Return on Assets ROA from the third quarter of 2026 to third quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Sep 27 2026 to Sep 28 2025 - CSIMarket
Johnson And Johnson's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period
Return on Assets, Quarterly Results, Trends, Rankings, Statistics
What is Johnson And Johnson's ROA in the third quarter of 2026? Johnson and Johnson achieved a return on average assets (ROA) of 7.83 % in its third quarter of 2026, which is below Johnson And Johnson's average return on assets, which stands at 12.03%.
ROA decreased relative to the period ending Jun 28 2026, due to the decline in net income.
However, within the Healthcare sector 90 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the second quarter of 2026 from 457 to 572.
In a bold move that reflects its commitment to innovation and growth, Johnson and Johnson (NYSE: JNJ) announced a significant expansion of its investment footprint in the United States. Over the next four years, the healthcare giant plans to allocate more than $55 billion towards advancements in manufacturing, research and development (RandD), and technology a 25% increase compared to the previous four-year investment cycle. This initiative builds upon the company s existing elevated U.S. investment levels, which have been positively influenced by policy changes like the 2017 tax reform.The announcement showcases Johnson and Johnson s position as a leader in the healthcare industry, underscoring its role as a comprehensive innovation powerhouse. The investments aim not only to bolster domestic manufacturing capabilities but also to drive cutting-edge research that can lead to new therapeutic breakthroughs. This move aligns with broader industry trends emphasizing local production and innovation to improve healthcare outcomes.
Comment on JNJ's ROA in the fiscal year ending 2025
In the fiscal year 2025 ROA improved to 13.46 % compared to prior year, due to annual net income growth of 90.56 % to $26,804.00 million, while value of Johnson And Johnson's overall assets grew just by 17.43 % to $199,210.00 million, compared to $199,210.00 a year before.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
